|
| Press Releases |
|
 |
|
| Wednesday, June 6, 2018 |
|
|
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting |
| Eisai Co., Ltd. and Purdue Pharma L.P. presented the results of two key Phase I clinical studies (Study 108 and Study 106) of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), from June 2 to 6 in Baltimore, Maryland, the United States. more info >> |
|
| Tuesday, June 5, 2018 |
|
|
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months |
| Eisai Co., Ltd. and Biogen Inc. announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (AB) levels in the brain measured by amyloid-PET (positron emission tomography). more info >> |
|
| Monday, June 4, 2018 |
|
|
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting |
| The data are included in presentations at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. LENVIMA and KEYTRUDA are not approved for use in combination in any cancer types today. more info >> |
|
| Thursday, May 31, 2018 |
|
|
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma |
| Eisai Co., Ltd. has announced the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
| Monday, May 28, 2018 |
|
|
Eisai: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" will be Presented at DDW2018 |
| Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that an oral presentation on PIII clinical study data on "GOOFICE 5mg Tablet". more info >> |
|
| Friday, May 25, 2018 |
|
|
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease |
| This novel mechanism of action elucidated is expected to lead to value enhancement and acceleration of the development of E6007 which aims to provide a new remedy for IBD patients. more info >> |
|
|
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib |
| The FDA has indicated that the extension of the Prescription Drug User Fee Act (PDUFA) date is needed to allow additional time for review of the application. more info >> |
|
| Wednesday, May 23, 2018 |
|
|
Eisai and Purdue Pharma to Present Latest Phase I Clinical Data on Lemborexant at 32nd Annual Sleep Meeting |
| Eisai Co., Ltd. and Purdue Pharma L.P. today announced they will present the latest data from two key Phase I clinical studies (Study 108 and Study 106). more info >> |
|
| Thursday, May 17, 2018 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate will be presented during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 1 to 5, 2018. more info >> |
|
| Monday, April 23, 2018 |
|
|
Eisai: Rights to Non-Opiod Severe Chronic Pain Treatment Prialt Transferred to Riemser |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive development and marketing rights for the non-opioid severe chronic pain treatment Prialt (ziconotide acetate) in Europe to Riemser Pharma GmbH. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Naoris Protocol Expands into the Nordics with Strategic Consulting Hub in Oslo
Jun 5, 2025 21:00 HKT/SGT
|
|
|
PlayX Showcases AI-Powered Transparency and Fairness at SiGMA Asia 2025 in Manila 
Jun 5, 2025 17:00 HKT/SGT
|
|
|
The Generation Essentials Group and Black Spade Acquisition II Co Complete Business Combination
Jun 5, 2025 11:33 HKT/SGT
|
|
|
Global Communities Unite at centralwOrld as Thailand Steps Forward on Global LGBTQ+ Stage with Central Pattana's Pride For All
Jun 5, 2025 08:30 HKT/SGT
|
|
|
TF International Facilitates Hong Kong's Successful Issuance of First Central Asian Sovereign Bond
Jun 4, 2025 22:28 HKT/SGT
|
|
|
Alpha Growth plc: Alpha Alternative Assets Fund Update ("AAAF")
Jun 4, 2025 15:00 JST
|
|
|
MHI Thermal Systems Receives A' Design Awards
Jun 4, 2025 14:10 JST
|
|
|
CBL International Limited Announces Share Repurchase Program
Jun 4, 2025 12:00 HKT/SGT
|
|
|
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Jun 4, 2025 12:58 JST
|
|
|
LIMA'25 Wraps up with RM11 Billion in Deals and Record Global Participation
Jun 4, 2025 11:00 HKT/SGT
|
|
|
Revigorate Announces Japan Launch, Asia Office, and New Portugal HQ
Jun 4, 2025 08:00 HKT/SGT
|
|
|
Implementation of Measures to Enhance Our Corporate Value in Connection with Toyota Industries Corporation
Jun 3, 2025 19:54 JST
|
|
|
Toyota Group to Accelerate Collaboration Towards Transforming into a Mobility Company Through Privatization of Toyota Industries Corporation
Jun 3, 2025 19:16 JST
|
|
|
Fujitsu accelerates digital transformation of financial institutions with newly systematized business strategy
Jun 3, 2025 18:46 JST
|
|
|
Fintech Forward Set to Return to Bahrain and Gather the Most Influential Leaders in Finance at its Third Edition in October 2025
Jun 3, 2025 17:45 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
